Paclitaxel Modulates the Proliferation and Differentiation of THP-1 Cells Exposed to Inactivated SARS-CoV-2 Virus
Authors:
- Everaldo HertzEHEveraldo Hertz
- Bárbara Osmarin TurraBTBárbara Osmarin Turra
- Fernanda dos Santos TrombiniFTFernanda dos Santos Trombini
- João Arthur Bittencourt ZimmermannJZJoão Arthur Bittencourt Zimmermann
- Cibele Ferreira TeixeiraCTCibele Ferreira Teixeira
- Verônica Farina AzzolinVAVerônica Farina Azzolin
- Ivo Emilio da Cruz JungIJIvo Emilio da Cruz Jung
- Ivana Beatrice Mânica da CruzICIvana Beatrice Mânica da Cruz
- Fernanda BarbisanFBFernanda Barbisan
Open Access
- 6 March 2025
- journal article
- Published by Revista Brasileira De Cancerologia (RBC) in Revista Brasileira de Cancerologia
- Vol. 71 (2)
Abstract
Introduction: Cancer patients were considered a high-risk group for COVID-19. Studies indicate that certain types of cancer, as breast cancer, may exhibit distinct immunological responses. Evidence suggests that paclitaxel (PTX), a chemotherapeutic agent widely used in the treatment of breast cancer, has immunomodulatory properties, which could contribute to attenuate the inflammatory response caused by the SARS-CoV-2 virus. Objective: To evaluate the effect of PTX on the THP-1 immune cell line activated by non-viral immunogenic agent 12-O-tetradecanoylphorbol-13-acetate (TPA) and by inactivated SARS-CoV-2 virus derived from the CoronaVac vaccine (CVac). Method: An in vitro study was conducted, initially determining the minimum concentration of CVac required to activate THP-1 cells. Subsequently, the cytotoxic action of PTX on THP-1 cells was investigated, followed by the analysis of the immunomodulatory effect of PTX through the evaluation of cell proliferation rate, cytomorphological differentiation, levels of nitric oxide, superoxide anion, and gene expression of the cytokines tumor necrosis factor-alpha and interleukin 10. Results: In 24-hour, 5% CVac activated THP-1 cells, triggering more significant proliferation and cell differentiation, compared to the control. No cytotoxic effects of PTX were observed. PTX reduced the cell differentiation rate and superoxide levels when co-exposed with TPA or CVac, but did not modulate cytokine gene expression. Conclusion: The data indicate that PTX could modulate in vitro immune activation in response to viral and non-viral immunogenic agents, suggesting that it could attenuate the inflammatory response to antigens, including SARS-CoV-2.Keywords
This publication has 36 references indexed in Scilit:
- Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumabCritical Reviews in Oncology/Hematology, 2023
- Macrophage polarization in THP-1 cell line and primary monocytes: A systematic reviewDifferentiation, 2022
- Understanding immune-modulatory efficacy in vitroChemico-Biological Interactions, 2021
- One‐year mortality and consequences of COVID‐19 in cancer patients: A cohort studyIUBMB Life, 2021
- Macrophage plasticity, polarization, and function in health and diseaseJournal of Cellular Physiology, 2018
- Assaying Cellular Viability Using the Neutral Red Uptake Assay2017
- THP-1 cell line: An in vitro cell model for immune modulation approachInternational Immunopharmacology, 2014
- A simple and inexpensive automated technique for measurement of serum nitrite/nitrateClinical Biochemistry, 2011
- Modulation of redox status and calcium handling by extremely low frequency electromagnetic fields in C2C12 muscle cells: A real-time, single-cell approachFree Radical Biology and Medicine, 2010
- Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assaysJournal of Immunological Methods, 1983